Check out FDAs new roster of bulk drug substances being pulled from use in compounding. Youll see BPC 157 and TB 500 among the various peptides added to the list of category 2 substances FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of HHS Secretary RFK Jr. just dropped major news: the FDA is removing 12 peptides from its restrictive Category 2 list reversing the 2023 crackdown that shut down compounding pharmacies and fueled BPC 157 Peptide Research, Benefits & US Sourcing Peptide Intel Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # Important Update on FDA Changes Concerning Peptides